ARTA
CASC

A.R.T. Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

A.R.T. Advisors’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,761
Closed -$44K – 1874
2017
Q3 		$44K Sell
10,761
-758
-7% -$2.9K ﹤0.01% 1264
2017
Q2 		$42K Sell
11,519
-22,500
-66% -$89.3K ﹤0.01% 1318
2017
Q1 		$140K Buy
+34,019
New +$143K 0.01% 1230
2016
Q3 		– Sell
-37,712
Closed -$213K – 1471
2016
Q2 		$213K Buy
37,712
+22,413
+146% +$152K 0.01% 1086
2016
Q1 		$116K Sell
15,299
-49,633
-76% -$382K 0.01% 1240
2015
Q4 		$864K Buy
+64,932
New +$1.12M 0.04% 639
2014
Q3 		– Sell
-13,229
Closed -$257K – 1665
2014
Q2 		$257K Buy
13,229
+4,955
+60% +$87.4K 0.01% 1038
2014
Q1 		$148K Sell
8,274
-2,303
-22% -$37.8K 0.01% 1197
2013
Q4 		$111K Hold
10,577
– – 0.01% 1184
2013
Q3 		$130K Buy
10,577
+8,034
+316% +$84.6K 0.01% 1186
2013
Q2 		$23K Buy
+2,543
New +$32.7K ﹤0.01% 1298

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

A.R.T. Advisors's CASC Position: Q4 2017 in Review

A.R.T. Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2017, closing a stake of 10,761 shares — an estimated $44K sold.

A.R.T. Advisors first reported a position in CASC in Q2 2013 and held it in 11 quarters. The position peaked at $864K in Q4 2015. 91 funds tracked by Wall St. Rank hold CASC as of Q4 2017.

  • A.R.T. Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • A.R.T. Advisors sold 10,761 Cascadian Therapeutics, Inc. shares in Q4 2017, an estimated $44K.
  • A.R.T. Advisors first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 11 quarters.
  • A.R.T. Advisors's Cascadian Therapeutics, Inc. position peaked at $864K in Q4 2015.
  • 91 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2017.

Based on A.R.T. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.